745 related articles for article (PubMed ID: 15577137)
1. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
2. [Next generation selective estrogen receptor modulators].
Chaki O
Clin Calcium; 2006 Jan; 16(1):145-52. PubMed ID: 16397365
[TBL] [Abstract][Full Text] [Related]
3. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
4. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
Gennari L
Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic agents for disorders of bone and calcium metabolism: Bazedoxifene].
Chaki O
Clin Calcium; 2007 Jan; 17(1):30-5. PubMed ID: 17211091
[TBL] [Abstract][Full Text] [Related]
6. Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Peterson GM; Naunton M; Tichelaar LK; Gennari L
Ann Pharmacother; 2011 Apr; 45(4):499-509. PubMed ID: 21467260
[TBL] [Abstract][Full Text] [Related]
7. Lasofoxifene in osteoporosis and its place in therapy.
Swan VJ; Hamilton CJ; Jamal SA
Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
[TBL] [Abstract][Full Text] [Related]
8. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
9. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
Gennari L
Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
[TBL] [Abstract][Full Text] [Related]
10. Lasofoxifene in postmenopausal women with osteoporosis.
Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
[TBL] [Abstract][Full Text] [Related]
11. Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats.
Weisenburger WP; Hagler AR; Tassinari MS
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):171-84. PubMed ID: 15282738
[TBL] [Abstract][Full Text] [Related]
12. Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats.
Terry KK; Cappon GD; Hurtt ME; Tassinari MS; Gupta U
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):150-60. PubMed ID: 15282736
[TBL] [Abstract][Full Text] [Related]
13. Lasofoxifene: CP 336156, CP-336156.
Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
[TBL] [Abstract][Full Text] [Related]
14. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
15. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
Archer DF
Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718
[No Abstract] [Full Text] [Related]
16. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
LaCroix AZ; Powles T; Osborne CK; Wolter K; Thompson JR; Thompson DD; Allred DC; Armstrong R; Cummings SR; Eastell R; Ensrud KE; Goss P; Lee A; Neven P; Reid DM; Curto M; Vukicevic S;
J Natl Cancer Inst; 2010 Nov; 102(22):1706-15. PubMed ID: 21051656
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
18. Another selective estrogen-receptor modulator for osteoporosis.
Becker C
N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
[No Abstract] [Full Text] [Related]
19. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene.
Gennari L; Merlotti D; Nuti R
Clin Interv Aging; 2010 Feb; 5():19-29. PubMed ID: 20169039
[TBL] [Abstract][Full Text] [Related]
20. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
